ReviewJournal of immunology research2017
Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.
Review in Journal of immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.Bone marrow transplantation · 2018Guideline
- Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Trial
- IgG Subclass Profiles of HLA Antibodies Enhance Prediction of C1q-Binding in Kidney Transplant Recipients.Diagnostics (Basel, Switzerland) · 2026Article
- Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention.Frontiers in immunology · 2026Review
- Expanding role of antibodies in kidney transplantation.World journal of transplantation · 2025Review
- Functional and phenotypic profiles of HLA-specific antibodies in relation to antibody-mediated kidney transplant rejection.Human immunology · 2025Article
- Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.Immunotherapy · 2025Review
- Contribution of long-lived plasma cells to antibody-mediated allograft rejection.Clinical transplantation and research · 2024Review
- Pushing the Survival Bar Higher: Two Decades of Innovation in Lung Transplantation.Journal of clinical medicine · 2024Review
- Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation.Cell reports. Medicine · 2022Article
- Non-HLA Antibodies in Kidney Transplantation: Immunity and Genetic Insights.Biomedicines · 2022Review
- Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.Cancer treatment and research · 2022Review
- Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Approaching the sensitized lung patient: risk assessment for donor acceptance.Journal of thoracic disease · 2021Review
- Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection.Transplantation direct · 2021Article
- HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.Frontiers in immunology · 2021Review
- Complement-activated interferon-γ-primed human endothelium transpresents interleukin-15 to CD8+ T cells.The Journal of clinical investigation · 2020Article
- 'Off-the-shelf' allogeneic CAR T cells: development and challenges.Nature reviews. Drug discovery · 2020Review
- The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.Frontiers in immunology · 2020Review
- B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome.Journal of immunology research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Consistent with Dr. Paul Terasaki's "humoral theory of rejection" numerous studies have shown that HLA antibodies can cause acute and chronic antibody mediated rejection (AMR) and decreased graft survival. New evidence also supports a role for antibodies to non-HLA antigens in AMR and allograft injury. Despite the remarkable efforts by leaders in the field who pioneered single antigen bead technology for detection of donor specific antibodies, a considerable amount of work is still needed to better define the antibody attributes that are associated with AMR pathology. This review highlights what is currently known about the clinical context of pre and posttransplant antibodies, antibody characteristics that influence AMR, and the paths after donor specific antibody production (no rejection, subclinical rejection, and clinical dysfunction with AMR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.